FDA Issues Warning Letters to Three API Repackers For GMP Violations

FDA warns repackers distributing pharmaceutical ingredients, including opioids, for putting consumers at risk with significant violations of manufacturing quality standards.

Quality_Control
Various API repackers have come under scrutiny over quality control issues • Source: Shutterstock

The US Food and Drug Administration has issued warning letters to three repackers of active pharmaceutical ingredients, including opioids, for significant violations of current good manufacturing practice requirements. The companies under question are B&B Pharmaceuticals, Asclemed USA – trading as Enovachem – and Spectrum Laboratory Products.

Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research said “the supply chain issues we have found in...

Welcome to Generics Bulletin

Create an account to read this article

More from Manufacturing

FDA Seeks To Encourage Onshoring With ANDA Prioritization Pilot

 
• By 

The latest incentive for firms to localize production in the US will see the FDA launch a pilot program to prioritize the review of US-manufactured and tested ANDA products.

The Generics Bulletin Podcast: Talking With AAM President And CEO John Murphy

 
• By 

Generics Bulletin editor Dave Wallace talks to John Murphy III, president and CEO of the US Association for Accessible Medicines, about the association’s latest annual savings report and key topics affecting the US off-patent market.

EU Critical Medicines Act Must Not Be ‘Watered Down’, Industry Urges

 
• By 

In a strongly-worded broadside against those who would seek to water down the EU’s Critical Medicines Act, Medicines for Europe has criticized the “selfishness” of certain actors in pursuit of lower prices at the cost of supply security.

Celltrion Spends A Billion To ‘Eliminate Tariff Risks’ With US Facility

 
• By 

Celltrion has paid out an initial $330m to acquire a US biologics manufacturing facility from Eli Lilly that it says will offer a “fundamental elimination of US tariff risks,” with the Korean biosimilars giant setting out plans to invest around a billion dollars in the plant overall.

More from Business

Sandoz Canada Looks To Savings With First Entresto Rival

 
• By 

North America will enjoy further generic competition to Entresto, after Sandoz became the first company to launch a generic version of Novartis’ heart failure blockbuster in Canada.

FDA Seeks To Encourage Onshoring With ANDA Prioritization Pilot

 
• By 

The latest incentive for firms to localize production in the US will see the FDA launch a pilot program to prioritize the review of US-manufactured and tested ANDA products.

AEON Biopharma Sets FDA Meeting To Advance Botox Biosimilar ABP-450

 
• By 

AEON Biopharma will meet with the FDA next month to review its 351(k) biosimilar pathway analytical plan for the firm’s proposed biosimilar to Botox.